Sperm-associated antigen 1 (SPAG1) has been shown to be expressed in high levels in pancreatic adenocarcinoma. SPAG1 is found in high levels in testis and a large proportion of pancreatic ductal adenocarcinomas (PDAC). It has been seen that in PDAC’s SPAG1 expression is predominantly cytoplasmic and confined to malignant cells. The extent and intensity of […]
| Inventor | Institute |
|---|---|
| Tatjana Crnogorac-Jurcevic | Queen Mary University of London |
| Cat. #: | 151749 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Developmental biology |
| Application: | IF ; IP ; WB |
| Target: | SPAG1 |
| Reactivity: | Human |
| Clone: | 10G1/2 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Sperm-associated antigen 1 (SPAG1) has been shown to be expressed in high levels in pancreatic adenocarcinoma. SPAG1 is found in high levels in testis and a large proportion of pancreatic ductal adenocarcinomas (PDAC). It has been seen that in PDAC's SPAG1 expression is predominantly cytoplasmic and confined to malignant cells. The extent and intensity of SPAG1 expression has been shown to be associated with stage and tumour nodal status and this has led to the suggestion that SPAG1 is a novel marker of PDAC progression. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Molecular weight: | 104 kDa |
| Immunogen: | Synthetic peptide SPA-3 (sequence designed to avoid TPR motifs – KTAPFNKEKERRKIEIQEVNE) |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | Sperm-associated antigen 1 (SPAG1) has been shown to be expressed in high levels in pancreatic adenocarcinoma. SPAG1 is found in high levels in testis and a large proportion of pancreatic ductal adenocarcinomas (PDAC). It has been seen that in PDAC's SPAG1 expression is predominantly cytoplasmic and confined to malignant cells. The extent and intensity of SPAG1 expression has been shown to be associated with stage and tumour nodal status and this has led to the suggestion that SPAG1 is a novel marker of PDAC progression. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Neesse et al. 2007. Oncogene. 26:1533-45. [PMID: 16983343] |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.